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ABSTRACT 
 
Objective Sonic hedgehog (Shh) signaling, androgens, and epithelial-mesenchymal 
transition (EMT) are related to prostate cancer (PCa) progression. The aim of this 
study is to investigate how Shh and androgen (dihydrotestosterone :DHT) signaling 
act in the prostate epithelial and stromal compartments and whether this signaling 
pathway drives EMT and promotes PCa progression. 
Material and Methods  LNCaP, normal prostate fibroblast (NPF) and 
cancer-associated prostate fibroblast (CPF) cells were studied with DHT and/or Shh 
signaling inhibitor, cyclopamine (Cy). Real-time RT-PCR was performed to evaluate 
the expressions of a potential Shh target gene, osteonectin (ON), and 
EMT-associated markers (E-cadherin, Vimentin, and N-cadherin). 
Immunohistochemical (IHC) studies using PCa prostatectomy samples were 
performed to assess the expression levels of ON, Gli-1, Androgen receptor (AR),  
Shh, E-cadherin, N-cadherin and Vimentin.  
Results  While DHT enhanced cell proliferation in CPF more than LNCaP or NPF, 
Cy inhibited cell proliferation enhanced by DHT in CPF. Real-time RT-PCR showed 
whereas both Shh and DHT induced N-cadherin and Vimentin, DHT also induced 
the expression of ON in LNCaP and Cy blocked these expressions in ON, 
N-cadherin and Vimentin (p=0.0084, p=0.0002 and p=0.0373, respectively). IHC 
results showed high expression of stromal ON (ONstr), not epithelial ON (ONepi), 
was significantly correlated with serum PSA (p=0.031), and high expression of Gli-1 
and low expression of ONstr with PSA recurrence (p=0.0114 and p=0.0005, 
respectively). 
  
2 
 
Conclusions  Shh and androgen signaling in prostate tumor and stromal 
compartments drives EMT, and thus may play some role in PCa progression. Shh 
signaling inhibitor, Cy may be one therapeutic strategy for PCa. 
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Introduction  
 
Hedgehog (Hh) is a developmental signaling pathway that regulates embryonic cell 
growth, body pattern formation and organogenesis in certain vertebrate tissues. Hh 
signaling leads to increased activity of Gli transcriptional factors and increased 
transcription of Gli target genes (1), and its signaling pathway driven by Hh ligands 
regulates the genes that are involved in cell proliferation, differentiation and cell 
motility (2). Although it is involved in the epithelial and stromal compartments 
during normal prostate development and in regulating growth, maturation and 
maintenance of the differentiated state in the adult (3), there is increasing evidence 
that dysregulated Hh signaling plays some role in prostate cancer (PCa) (4). Also, 
stromal fibroblasts respond to and actively react with stimuli from cancer epithelium 
(5).  
On the other hand, androgen regulates the expression of several key molecules 
in the Hh signaling pathway including members of the Gli transcription factor family. 
The potential relationship between androgen and the expression of some critical 
molecules in the Hh signaling pathway might explain some of the aberrations in Hh 
signaling reported to occur in PCa. Androgen depletion strongly upregulates 
expression of Hh ligands and Gli targets, and markedly elevates sonic hedgehog 
(Shh) expression in human PCa cells (1). This indicates the potential for chronic 
androgen deprivation therapy to create a Hh signaling environment for primary or 
metastatic prostate tumors that might improve the response of these tumors to 
therapy on a long-term basis (4). Therapeutically targeting Hh signaling in human 
primary and/or bone metastatic PCa could therefore prove to be beneficial (6).  
Recently, osteonectin (ON) was identified in interaction between normal human 
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prostate stromal cells and PCa; moreover, recombinant Shh protein was identified as 
not only a new Shh-Gli1 target gene but possible Shh target gene in our previous 
work (7). In addition, epithelial-mesenchymal transition (EMT) is known to promote 
cancer progression via loss of cell adhesion, repression of E-cadherin expression and 
increased cell mobility; there are several oncogenic pathways that induce EMT (8).  
In this study, we investigated how Shh signaling and representative androgen, 
dihydrotestosterone (DHT) works in prostate epithelial and stromal compartments 
and drive EMT in PCa progression, using cell proliferation assays and real time 
reverse transcription polymerase chain reaction (RT-PCR). We used 
immunohistochemical (IHC) analyses to explore the significant markers for 
aggressive clinical PCa, including high serum prostate specific antigen (PSA) and 
high Gleason scores (GSs), especially focusing on potential epithelial or stromal Shh 
signaling target genes, ON expression, and biochemical recurrence in PCa patients. 
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Material and Methods 
 
Cell culture and conditioned medium (CM) collection 
Established LNCaP PCa cells were cultured by standard methods using the Roswell 
Park Memorial Institute-1640 medium (RPMI-1640 medium, Sigma Chemical, St. 
Louis, MO) supplemented with 10% fetal bovine serum (FBS) (MP Biomedicals Inc, 
Seven Hills, Australia). Tissues for primary prostate stromal culture were obtained 
from consenting patients with PCa undergoing radical prostatectomy at the Emory 
University School of Medicine, Atlanta, GA, USA. This study was approved by the 
Institutional Review Board (IRB) Committee. The origins of the stromal fibroblasts 
were: 1) normal prostate fibroblast (NPF) from normal/benign lesions of the human 
prostate gland and 2) cancer-associated prostate fibroblasts (CPF) from cancerous 
lesions of prostatectomy specimens as described previously (9). The Hh signaling 
inhibitor cyclopamine (Cy) (Toronto Chemical Inc., Toronto, ON, Canada) was 
dissolved and diluted with dimethyl sulfoxide (DMSO) to a 10 mM stock solution. 
Androgen, DHT (Sigma, St. Louis, MO, USA) was dissolved and diluted with 
ethanol to a 10 mM stock solution. Recombinant human Shh protein (Neuromics, 
Edina, MN, USA) was dissolved and diluted by DMSO with 0.1 % weight of PBS at 
25 g/ml of the stock solution. For conditioned medium (CM) collection, cells were 
cultured in RPMI-1640 medium supplemented with 10% FBS until 50% confluent. 
The cells were washed once in phosphate-buffered saline (PBS) and twice in 
T-medium with penicillin. Thereafter, the cells were incubated in 10ml of T-medium 
with penicillin. After 48 hours of incubation, CM was collected, centrifuged, and 
aliquat was stored at -20°C until use (9) .  
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Cell proliferation assay 
Cell proliferation was investigated by Alamar Blue assay (BioSource International 
Inc. Camarillo, CA, USA) in PCa LNCaP cells and prostate stromal cells (NPF and 
CPF). The cells were initially seeded in a 100 mm cell culture dish in RPMI-1640 
medium supplied with 10% FBS. Near 80% confluence, the cells were seeded in 
96-well plates at 5  103 cells/well for 24 hours, then switched to FBS free medium. 
First, to evaluate the efficacy of both Cy and DHT in a dose-dependent manner in 
LNCaP cells, 96-well plates were divided into 4 divisions, one division as control 
and the other three divisions treated with three different doses of Cy or DHT. After 
48 hours, Alamar Blue reagent was added at 10 micron per well followed by 
incubation at 37 ºC and 5 % CO2 for 1 hour, followed by recording the absorbance of 
the converted dye at a wavelength of 570 nm. This was also repeated after 96 and 
144 hours. For the LNCaP, NPF, and CPF cell plates, each was divided into 4 
divisions: Group-1, a vehicle-control group with DMSO added; Group 2, DHT added 
at a concentration of 10 µM; and Group 3, both Cy added at a concentration of 5µM 
and DHT added together at the same concentration. In addition, in order to evaluate 
the effect of stromal cells CM on PCa cell proliferation, CM from NPF and CM from 
CPF were added to LNCaP and cell proliferation was assayed after 48 hours 
treatments. CM was prepared according to a previous study (9). All experiments 
were carried out in triplicate. Data were expressed as mean ± standard deviation 
(S.D.) and evaluated for statistical significance.  
 
RT-PCR 
Total RNA was isolated from confluent monolayers of cells using TRIZOL Reagent 
(Invitrogen, Carlsbad, CA, USA), followed the manufacturer’s instructions. 
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First-strand cDNA was synthesized from total RNA (0.2 μg) using SuperScript II 
reverse transcripase (Invitrogen) with random hexanucleotide primers. Quantitative 
real-time PCR was performed using SYBR Green PCR Master mix and the ABI 7500 
Fast Real-Time PCR System (Applied Biosystem., Carlsbad, CA, USA). A hot start 
at 95 °C for 5 minutes was followed by 40 cycles for denaturation at 95 °C for 15 
seconds, annealing of the primers at 60 °C for 30 seconds and elongation at 72 °C for 
30 seconds. Data were normalized to β-actin and represented as the average ratio of 
duplicates, according to the ΔΔ Ct method. The oligonucleotide primer sets are 
shown in Table I. These primers were designed in our laboratory. 
 
IHC study 
IHC staining of radical prostatectomy (RP) specimens of 25 patients from the 
Department of Urology, Akashi Municipal Hospital, was performed as previously 
described (9). The distribution of GSs was 6 in 3 patients, 7 in 14 patients, 8 in 5 
patients and 9 in 3 patients. This research was carried under compliance with the 
Helsinki Declaration. Briefly, the sections were then incubated with the following 
antibodies: anti-human androgen receptor (AR) rabbit polyclonal antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), anti-human Gli-1 rabbit polyclonal 
antibody (Santa Cruz Biotechnology), anti-human ON mouse monoclonal antibody 
(Abnova, Jhongli, Taiwan), anti-human Shh rabbit polyclonal antibody (Santa Cruz 
Biotechnology), anti-human E-cadherin mouse monoclonal antibody (DAKO, 
Carpinteria, CA, USA), anti-human N-cadherin mouse monoclonal antibody 
(DAKO) and anti-human Vimentin mouse monoclonal antibody (DAKO). The 
sections were then incubated with biotinylated goat anti-mouse or rabbit 
immunoglobulin G (Vector Laboratories, Burlingame, CA). After incubation in 
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avidin–biotin peroxidase complex for 30 minutes, the samples were exposed to 
diaminobenzidine tetrahydrochloride solution and counterstained with methyl green 
(Vector Laboratories) or hematoxylin.  
 
IHC analyses 
IHC staining results were scored by two independent observers who were blinded to 
the clinicopathological data. If discordant interpretations were obtained, differences 
were resolved by joint review and/or consultation with a third observer experienced 
in IHC pathology. Both cytoplasmic and nuclear staining for AR and only 
cytoplasmic staining for Gli-1 and Shh was considered positive as previously 
reported (10, 11). IHC was evaluated by the percentage of positive cells. For Gli-1 
and Shh, if more than 10% of the tumor cells were stained, gene expression was 
considered to be “positive” (<10 %, −; 10-50 %, 1+; 50- 90 %, 2+; >90 %, 3+) (11). 
The frequency of ON IHC was scored as 0 when no staining of the tumor cells was 
observed, weak staining (score 1) when less than 30 % of the tumor cells were 
stained, moderate staining (score 2) when 30-60 % of the tumor cells were stained, 
and strong staining (score 3) when more than 60 % of the tumor cells were stained. 
The total IHC score was determined as the sum of the frequency and intensity scores 
for tumor cells (low expression score: 0-3 and high expression score: 4-6) (12). In 
addition, the staining of ON was recorded as positive in epithelial (ONepi) or 
positive in stroma (ONstr). The staining localization of E-cadherin, N-cadherin and 
Vimentin IHC were classified as nuclear, cytoplasmic and membranous. The staining 
intensity was scored as 0 (negative), 1+ (weak), 2+ (medium) or 3+ (strong). The 
percentage of stained cells was categorized into; 1= 0-10% stained cells; 2= 11-50% 
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stained cells; 3= >50% stained cells (13). We showed IHC figures with normal 
power (x 200) and high power (x 400) images. 
The expression levels (histopathological gradings) of ON, Gli-1, AR,  Shh, 
E-cadherin, N-cadherin and Vimentin were investigated including the comparison 
between normal and cancer area and analyzed in correlation with clinicopathological 
data such as patients’ initial PSA level, GSs in the prostatectomy specimen, and 
biochemical recurrence. Biochemical recurrence is defined as PSA rise-up to 0.2 
ng/ml or PSA nadir > 0.1 ng/ml after prostatectomy. 
 
Statistical analysis 
Statistical analysis was conducted with the JSTAT - Java Virtual Machine Statistics 
Monitoring Tool (Sun Microsystems, Inc., Santa Clara, CA). The results of in vitro 
experiments were analysed by Student`s t test. The correlations of the protein 
expression in immunohistochemical analyses (ONepi, ONstr, Gli-1, AR, Shh, 
E-cadherin, N-cadherin and Vimentin) with clinicopathological data were analysed 
by the Spearman rank-order correlation. Statistical significance was established at 
p<0.05. 
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Results 
 
LNCaP cell proliferation after treatment with cyclopamine 
Hh signaling inhibitor, Cy (5, 10, and 20 µM) inhibited LNCaP cell proliferation in 
96 hours treatments and revealed its inhibition in a dose-dependent manner 
especially in 144 hours treatments (Fig. 1). 
 
Comparison of LNCaP, NPF and CPF responses to DHT and cyclopamine  
We compared the responses of LNCaP cell lines and NPF or CPF to DHT and DHT 
+ Cy in order to investigate how the prostate tumor and stromal compartments react 
to DHT and Cy. First, the results showed that DHT tended to enhance cell 
proliferation in CPF x 1.71 times (significant difference from control; p<0.0001) (Fig. 
2C) more than in LNCaP (x 1.14) (significant difference from control; p=0.0001) 
(Fig. 2A) or NPF (x 1.13) (significant difference from control; p>0.05 (Fig. 2B). 
Next, the addition of Cy to DHT showed significantly inhibited effects in LNCaP (x 
0.917; p=0.0059) and CPF (x 0.788; p=0.0006), but not NPF (x 0.912; p=0.0887). 
These data suggested that CPF have potentially more reaction to DHT with the 
addition of Cy than LNCaP or NPF, indicating that Cy could have more of an effect 
on cancer associated stromal cells but not necessarily from cancer cells nor 
normal/benign prostate stromal cells. (Fig. 2).  
 
The comparison of LNCaP cell proliferation in the presence of NPF CM and CPF 
CM 
We compared the LNCaP cell proliferation assay with CM from NPF and CPF.  
LNCaP cells in the presence of CM from grew faster than those with CM from NPF 
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(p=0.0017) (Fig 3). 
 
Shh and cyclopamine effects on EMT in LNCap 
Recombinant Shh protein (1 g/ml) suppressed the expression of E-cadherin (x 
0.29)compared with vehicle control (p=0.0266) and enhanced the expression of 
N-cadherin (x 5.4) and Vimentin (x 215) in real time RT-PCR,and these changes in 
N-cadherin and Vimentin were blocked by the Shh signaling inhibitor Cy (p=0.0344 
and p=0.0158, respectively) (Fig. 4A). 
 
ON and EMT expressions by DHT and/or cyclopamine in LNCap 
DHT induced the expression of the potential Shh signaling target gene ON (x 31), 
N-cadherin (x 5.3) and Vimentin (x 1.5), and suppressed the expression of 
E-cadherin (x0.67). Cy blocked these enhanced- or suppressed- expressions. 
However, the effects of Cy or DHT+Cy were indicated in ON, N-cadherin and 
Vimentin (in Cy, p=0.0084, p=0.0002 and p=0.0373, respectively) (in DHT+Cy, 
p=0.0002, p=0.0007 and p=0.0085, respectively) (Fig. 4B and 4C). 
 
IHC staining results 
Representative findings from IHC staining of PCa specimens for expression of ON, 
and Gli-1 are shown in Fig. 5. Strong epithelial (Panel A; A-1: normal power image 
(x 200) and A-2: high power image (x 400); the same shall apply hereafter.), stromal 
(Panel B (B-1 and B-2)), expressions of ON in PCa areawere shown. Panel C showed 
strong expression of Gli-1 in the PCa area (Panel C-1 and C-2). Panel D showed 
strong expressions of AR in PCa area (Panel D-1 and D-2). Panel E also showed 
strong expressions of Shh in PCa area (Panel E-1 and E-2). Panel F showed 
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down-regulation in the epithelium of E-cadherin in PCa area (Panel F-1 and F-2). 
Panel G showed strong epithelial expressions of N-cadherin in PCa area (Panel G-1 
and G-2). Panel H showed strong stromal expressions of Vimentin in PCa area 
(Panel H-1 and H-2) (Fig. 5).  
 
Relationship between IHC analyses and patients’ clinical and pathological data 
Statistical analyses of clinical data and IHC results (Table II) showed that ONstr had 
a significant correlation with serum PSA (p=0.031). Importantly, PCa recurrence 
had a significant correlation with Gli-1 (p=0.0114) and low expression of ONstr 
(p=0.0005), suggesting that the expression of ONstr may correlate to PCa initiation 
as shown in our previous work (9). The significant correlation was not found 
between clinicopathological data and EMT marker (E-cadherin, N-cadherin and 
Vimentin). Also, the significant correlation between serum PSA and IHC stainings 
was not found in both normal and cancer tissue (Table III). As to cytoplasmic AR 
stainings, we did not find that cytoplasmic staining was specific to AR in all Gleason 
grades (p=0.1489). 
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Discussion 
 
The Hh signaling pathway has an axial function in the development and patterning of 
many endodermally derived tissues, and evidence from several studies suggests that 
Hh pathway activity in PCa promotes tumor growth, invasion, metastasis, and 
hormone independence (7). In recent PCa chemotherapy, targeting the Hh pathway 
has shown promising results, and Smoothened (Smo) and Glis have been considered 
primary targets for anti-Hh therapeutics (14). A corn lily steroidal alkaloid, Cy, 
inhibits intracellular Hh signaling by blocking the activity of Smo. Efforts to develop 
and apply anti-Hh therapeutics have been ongoing for several years (15).  
In this study, CPF reacted to androgens (DHT) more than LNCaP or NPF and to 
Cy in the presence of DHT more than LNCaP or NPF, and also our CM study 
showed CM from CPF significantly affected LNCapP cell proliferation more than 
NPF. These results suggest, taken together with our previous study (16), that CPF 
may be a reactive stroma especially in the presence of androgens (DHT) and may 
have different proliferative signaling from NPF in this condition. Our findings in 
CPF may offer a hint for understanding androgen-dependent PCa (LNCaP) cell 
heterogeneity and the evolution from androgen-dependent to independent PCa. These 
in vitro results, taken together with our previous studies (5), suggest that Cy and 
other Hh signaling inhibitors may be a possible therapeutic strategy for PCa not only 
at an early stage, equivalent to the situation of LNCaP mainly surrounded by NPF in 
vitro, but in advanced stage cancer, equivalent to where LNCaP is mainly surrounded 
by CPF in vitro (1, 6, 16) in the presence of androgens (DHT). Interestingly, these 
findings were partly different from our previous work using androgen-independent 
PCa cells especially in the response to NPF and CPF including their derived CM (9). 
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This difference may be a hint for understanding of change of androgen-dependent to 
–independent feature in PCa cells for their growths  
The complex roles of ON in different tumors may be attributed to the 
bioavailability of either the whole molecule or its cleavage products (17). Since ON 
was identified as a major bone-derived chemo-attractant for PCa cells in vitro (18), it 
may play a role not only in PCa bone metastasis but also for its growth or 
proliferation. Jacob et al. stated that ON enhanced invasion and migration of PCa 
(19). Consistent with those data, our statistical analysis of clinical data and PCa IHC 
results showed that only ONstr, not ONepi, had significant correlation with the 
serum PSA level of PCa patients (p=0.031). Additionally, our androgens 
(DHT)-induced-ON expression was also abrogated by Cy and it suggests that 
androgens (DHT) might be located upstream of Cy. In addition, our Gli-1 expression 
was significantly related to PCa recurrence and ONstr was significantly related to 
non PCa-recurrence, indicating that Gli-1 expression may have involvement with 
PCa progression while ONstr expression might lead to early status PCa as shown in 
our previous works (9).  
EMT is well known to be related to tumor invasiveness and metastasis in human 
carcinomas, including PCa (20-24), by upregulation of mesenchymal genes such as 
Vimentin and N-cadherin and down-regulation of epithelial-associated markers such 
as E-cadherin (21). Maitah et al. showed that transcriptional up-regulation of Shh by 
TGF-β1 induced EMT phenotype and aggressive behavior in non-small-cell lung 
cancer cells (25) and Elkhatib et al. stated that blocking the Hedgehog pathway in 
cyclopamine inhibited EMT (26). We demonstrated that the Shh-induced and 
DHT-induced expressions of EMT markers (E-cadherin, Vimentin, and N-cadherin,) 
in LNCaP cells were blocked by Cy, suggesting, along with the results of ON 
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expression studies, that Cy and its analogues could be a therapeutic strategy for PCa 
as mentioned above and that EMT markers may locate downstream of Shh and/or 
androgen (DHT) signaling. However, differently from in vitro data, we could not 
find the correlation between clinicopathological data and EMT markers in IHC. 
Lehmann et al. stated that intrinsic, genetically regulated pathways and 
environmental factors affected physiology and phenotype of tumor cells in EMT 
transcription factor (27), suggesting our patients group in vivo might have unique 
environmental factors which were not driven by EMT tested in this study. 
We would like to emphasize the limitations of this study. Future studies with a 
larger number of patient’s samples are needed for definite evaluation of the markers 
of PCa progression. In addition, although this study focused on the relationship 
between Shh signaling, androgens (DHT) and EMT in the prostate tumor and stromal 
compartments in PCa and the relationship of their downstream targets with clinical 
data (serum PSA, high GSs, and recurrence in PCa patients), there might be other 
molecules not involved in the regulation of Shh signaling which are more closely 
associated with PCa patient prognoses. In addition, the mechanistic study was lack of 
protein level analyses by such as western blots partly because of the problems of 
antibodies and our study did not obtain convincing results for EMT marker 
expression in our IHC staining or a signaling link with Shh and/or androgens (DHT). 
This should also be explored with a greater number of patient samples to further 
understand the relationship between Hh signaling and EMT markers in PCa 
progression.  
   In conclusion, Shh signaling plays a role in PCa through a relationship with 
androgens and drives EMT in the tumor and stromal compartments. DHT-induced 
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ON expression or reactive prostate stroma (cancer-associated stroma) may be a 
possible target in PCa progression especially in androgen independent status and Hh 
signaling inhibitor Cy might be a potential therapeutic strategy for PCa.  
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Figure legends 
 
 
Fig. 1  In vitro cell proliferation assay in LNCaP cell line treated with DMSO 
(vehicle control) or 3 sets of concentrations of hedgehog (Hh) signaling inhibitor, 
Cyclopamine (Cy: 5, 10, and 20 µM). Cy inhibited LNCaP cell proliferation in 96 
hours treatments and revealed its inhibition in a dose-dependent manner especially in 
144 hours treatments. Y axis revealed the relative cell proliferation with setting 
vehicle control at the initiation of treatments (0 hour) as 1.0 and X axis showed the 
time course (0, 48, 96, and 144 hours). 
 
Fig. 2  In vitro cell proliferation assay in three cell lines: (Panel A) LNCaP, (Panel 
B) NPF, normal prostate stromal fibroblasts, (Panel C) CPF, cancer-associated 
prostate stromal fibroblasts, treated with DMSO (vehicle control) or 
dihydrotestosterone (DHT (10 µM) or dihydrotestosterone and Cyclopamine (DHT 
(10 µM) + Cy (5 µM), respectively). Panels A, B, and C demonstrated that DHT 
enhanced cell proliferation in LNCaP and CPF and the addition of Cy significantly 
inhibited proliferation in these cells. In them, considering p-value and the ratio of 
change by DHT and Cy, CPF may respond to DHT and DHT + Cy. Each column 
represents triplicate averages ± SD. All significant differences were shown as p-value. 
N.S. = “not significant”. Y axis revealed the relative cell proliferation with setting 
vehicle control at the initiation of treatments (0 hour) as 1.0. 
 
Fig. 3  The comparison of the growth in LNCaP cells in the presence of NPF- and 
CPF-derived conditioned medium (CM). 
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Fig. 4  RNA expressions of EMT markers (E-cadherin, N-cadherin and Vimentin,) 
were investigated in the presence of recombinant sonic hedgehog (Shh) protein with 
or without Cyclopamine (Cy) in LNCaP cells. Shh induced the expression of 
N-cadherin and Vimentin and their enhanced expressions were abrogated by Cy. 
Conversely, Shh suppressed the expression of E-cadherin and its suppression was 
recovered by Cy (Panel A). RNA expressions of potential Shh signaling target gene, 
Osteonectin (ON) and EMT markers (E-cadherin, N-cadherin and Vimentin,) were 
investigated in the presence of dihydrotestosterone (DHT) with or without Cy in 
LNCaP cells. DHT enhanced the expressions of ON, N-cadherin and Vimentin, and 
these enhanced expressions were blocked by Cy even though the effect of Cy or Cy 
+DHT were varied in each marker. Conversely, DHT suppressed E-cadherin 
expression and Cy or Cy +DHT blocked this suppressed expression. However, the 
effect of Cy or Cy +DHT was not consistent (Panel B and C). 
 
Fig. 5  Typical outcomes of immunohistochemical (IHC) staining of PCa specimens 
with ON, Gli-1, AR, Shh, E-cadherin, N-cadherin and Vimentin antibodies. Panel A 
showed strong epithelial expression of ON in the PCa area (An arrow indicates the 
positive cells in epithelial area.) (Panel A; A-1: normal power image (x200) and A-2: 
high power image (x400); the same shall apply hereafter.).  
. Panel B revealed strong stromal expression of ON in the PCa area (An arrow 
indicates the positive cells in stroma.) (Panel B (B-1 and B-2)). Panel C showed 
strong cytoplasmic expression of Gli-1 in the PCa area (An arrow indicates the 
positive cells in cytoplasma.) (Panel C-1 and C-2). Panel D showed  the epithelial 
and stromal expression of AR in the PCa area (An arrow indicates the positive cells 
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in epithelium.) (Panel D-1 and D-2). Panel E showed the epithelial and stromal 
expression of Shh in the PCa area (Arrows indicate the positive cells in epithelium 
(single arrow) and stroma (double arrows).) (Panel E-1 and E-2). Panel F showed the 
low epithelial expression of E-cadherin in the PCa area  (Panel F-1 and F-2). Panel 
G showed the epithelial expression of N-cadherin in the PCa area (An arrow 
indicates the positive cells in epithelium.) (Panel G-1 and G-2). Panel H showed the 
stromal expression of Vimentin in the PCa area (An arrow indicates the positive cells 
in stromal area.) (Panel H-1 and H-2). 
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Table I   PCR primer 
 
human osteonectin (ON): 5'-GAGACCTGTGACCTGGACAATG-3' (forward) and   
                                   5'-GGAAGGAGTGGATTTAGATCACAAGA-3' (reverse)
human E-cadherin: 5’-TGCCCAGAAAATGAAAAAGG-3’ (forward) and 
                          5’-GTGTATGTGGCAATGCGTTC-3’ (reverse)
human N-cadherin: 5’-ACAGTGGCCACCTACAAAGG-3’ (forward) and  
                          5’-CCGAGATGGGGTTGATAATG-3’ (reverse)
human Vimentin: 5’-CAACCTGGCCGAGGACAT-3’(forward) and 
                       5’-ACGCATTGTCAACATCCTGTCT-3’(reverse)
β-actin:  5'-CAAGGCCAACCGCGAGAAGATGAC-3' (forward) and 
              5'-GCCAGAGGCGTACAGGGATAGCACA-3' (reverse)  
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Table II  Correlation of the protein expression in immunohistochemical analyses 
        with serum PSA or high Gleason scores (≥8) or PSA recurrence 
 
serum PSA  PSA recurrence
p-value p-value p-value
ONepi 0.221 0.168 1.0000
ONstr 0.031 0.688 0.0005
Gli-1 0.251 0.635 0.0114
Shh 0.859 0.100 0.5673
AR 0.841 0.060 0.3127
E-cadherin 0.388 0.339 0.5674
N-cadherin 0.221 0.194 0.8229
     Vimentin 0.432 0.135 0.6448
*bold:     statistically significant (p<0.05)
 ON epi: epithelial osteonectin 
 ON str:  stromal osteonectin
high Gleason
scores (>8)
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Table III  Correlation of the protein expression in immunohistochemical analyses 
         of normal prostate area and prostate cancer area with serum PSA   
 
serum PSA serum PSA
(normal) (cancer)
p-value p-value
Gli-1 0.5326 0.9071
Shh 0.9003 0.7494
AR 0.9304 0.7471
ONepi 0.6132 0.1456
ONstr 0.3284 0.1518
E-cadherin 0.0749 0.3583
N-cadherin 0.4773 0.1804
Vimentin 0.5177 0.3914
  ON epi: epithelial osteonectin 
  ON str:  stromal osteonectin  
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